SRRK

Rating buyAI Memo

Scholar Rock

As of 2026-02-04/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-02-04 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Potential lead-program clinical readout (assumed window) • 2026-12-31

Base target: $50 / p=60% prob

Biggest risk

Negative or ambiguous clinical results, regulatory setbacks, or the need for dilutive financing would compress valuation toward the analyst low (42.0); event-driven downside could be swift given coverage concentration.

Invalidation

Break below $42 or thesis failure.

What would change my mind?

Positive clinical readouts and a constructive partnership or commercial update validate the mechanism and could re-rate shares toward the analyst high (63.0). Limited near-term dilution and clear regulatory progress would reinforce upside within 12 months.

Research note

Recommendation

buy

Confidence

medium

As of

2026-02-04

Base target

$50

p=60%

Bull target

$63

p=20%

Bear target

$42

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Quarterly results / corporate update
Analyst coverage updates / price-target revisions
Partnerships / longer-term business development

BearKey bullets

Clinical trial failure or missed endpoints
Need for additional financing / dilution
Regulatory delay or unfavorable label

WatchKey bullets

Potential lead-program clinical readout (assumed window)

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $50 (p=60%)

Target spread vs base: +25% / -17%

Scenario probabilities

Bull Target: $63 (p=20%)Base Target: $50 (p=60%)Bear Target: $42 (p=20%)

Commentary

Analyst coverage skews constructive with a median target above the current anchor and several recent upward revisions cited [#SERP-2], [#SERP-7]. Coverage dispersion (low-to-high spread) implies event-driven volatility around clinical and partnership catalysts [#SERP-3].

As of 2026-02-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Quarterly results / corporate update
Analyst coverage updates / price-target revisions
Partnerships / longer-term business development

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-02-04Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$50.34

Range (USD)

$42.00 - $63.00

Count

Query: Scholar Rock Holding Corp Common (SRRK) analyst consensus price target high low average

Scholar Rock Holding Corp (SRRK) Stock Forecast & Price Target
Search result #1
According to projections from 14 analysts, the average 12-month price target for Scholar Rock is 50.36, with a high estimate of 60 and a low estimate of 42.
Open source
Consensus Scholar Rock Holding Corporation - MarketScreener
Search result #2
Analysts' Consensus ; Mean consensus. BUY ; Number of Analysts. 16 ; Last Close Price. 44.97USD ; Average target price. 49.36USD ; Spread / Average Target. +9.76%.
Extracted: $44.97, $49.36Open source
Scholar Rock Holding Corp (SRRK) Stock Forecast ... - TipRanks
Search result #3
The average price target is $51.70 with a high forecast of $60.00 and a low forecast of $42.00. The average price target represents a 19.87% change from the ...
Extracted: $51.70, $60.00, $42.00Open source
SRRK Stock Forecast: Analyst Ratings, Predictions & Price Target ...
Search result #4
Wall Street analysts have set a price target of $50.64, reflecting a 0.00% increase from the current stock price. What is the 2026 price prediction for SRRK?
Extracted: $50.64Open source
SRRK / Scholar Rock Holding Corporation (NasdaqGS) - Forecast ...
Search result #5
The average one-year price target for Scholar Rock Holding Corporation is $50.34. The forecasts range from a low of $42.42 to a high of $63.00. Read More.
Extracted: $50.34, $42.42, $63.00Open source
SRRK - Scholar Rock Holding Corp Stock - AnaChart
Search result #6
Highest price target for SRRK is $60, Lowest price target is $44, average price target is $50.75. Most recent stock forecast was given by MICHAEL YEE from UBS ...
Extracted: $60.00, $44.00, $50.75Open source

Scenarios

Bull Target (Scenario probability)

$63 / p=20% prob

Base Target (Scenario probability)

$50 / p=60% prob

Bear Target (Scenario probability)

$42 / p=20% prob

Analysis 2026-02-04 · RankAlpha Sentiment AI

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-12-31
Potential lead-program clinical readout (assumed window)
Binary efficacy/safety readout could materially re-rate the stock; expected_date is an assumed window end due to no public schedule [#SERP-1].
Prob 40.00% • Move 30.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Quarterly results / corporate update
2026-05-05
Quarterly results and management commentary that typically move small-/mid-cap biotech shares; analysts will watch guidance and cash runway [#SERP-2].
Prob 95% • Move 8% • Priced-in 60%
Analyst coverage updates / price-target revisions
2026-05-05
Broker notes and target changes (recent upgrade activity noted) can shift sentiment and flows quickly [#SERP-7].
Prob 60% • Move 10% • Priced-in 50%

Long-term Catalysts

Months to a year

Partnerships / longer-term business development
2027-02-03
Licensing, partnerships or commercialization progress would de-risk revenue and could re-rate valuation over multiple quarters [#SERP-5].
Prob 25% • Move 25% • Priced-in 15%

Risks

Clinical trial failure or missed endpoints
Need for additional financing / dilution
Regulatory delay or unfavorable label

Peers

Symbol	Summary
REGN	Established biologics developer; useful comparator for regulatory/commercial execution and partnership outcomes.
AMGN	Large biologics company with deep commercialization experience; a benchmark for launch and scaling dynamics.
BIIB	Clinical-stage/large-cap biotech with comparable R&D and regulatory complexity; relevant for program-risk comparisons.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Scholar Rock Holding Corp Common (SRRK) analyst consensus price target high low average
Analysis date: 2026-02-04

Loading AI feed…

Symbol

Summary

REGN

Established biologics developer; useful comparator for regulatory/commercial execution and partnership outcomes.

AMGN

Large biologics company with deep commercialization experience; a benchmark for launch and scaling dynamics.

BIIB

Clinical-stage/large-cap biotech with comparable R&D and regulatory complexity; relevant for program-risk comparisons.